Share

November 02, 2021; 97 (18) Research Article

Risk of Aneurysm Rupture After Thrombolysis in Patients With Acute Ischemic Stroke and Unruptured Intracranial Aneurysms

Jyri Juhani Virta, Daniel Strbian, Jukka Putaala, Miikka Korja
First published October 6, 2021, DOI: https://doi.org/10.1212/WNL.0000000000012771
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
249

Share

Article Information

vol. 97 no. 18 e1790-e1798
DOI: 
https://doi.org/10.1212/WNL.0000000000012771
PubMed: 
34615686
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received May 17, 2021
  • Accepted in final form August 12, 2021
  • First Published October 6, 2021.

Article Versions

Copyright & Usage: 
© 2021 American Academy of Neurology

Author Disclosures

    1. Jyri Juhani Virta, MD, PhD,
    2. Daniel Strbian, MD, PhD,
    3. Jukka Putaala, MD, PhD and
    4. Miikka Korja, MD, PhD
  1. Jyri Juhani Virta, MD, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) Helsinki University Hospital Clinical Research Funds (State funding, Finland), grant numbers Y124920063 and Y124930064, year 2020 and 2021

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Maire Taponen Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Daniel Strbian, MD, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Stroke, Associate Editor, 2019- European Stroke Journal, Editorial board member, 2016-

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) The Helsinki University Central Hospital (HUCH) governmental subsidiary (EVO) funds for clinical research, minor role, 2019-2021

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Jukka Putaala, MD, PhD and
    4. Scientific Advisory Boards:

    1. (1) Advisory Board: Boehringer-Ingelheim (2) Advisory Board: Bayer (3) Advisory Board: BMS-Pfizer (4) Advisory Board: Portola (5) Advisory Board: Herantis Pharma

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Speaker honoraria: Boehringer-Ingelheim (2) Speaker honoraria: Bayer (3) Speaker honoraria: BMS-Pfizer (4) Speaker honoraria: Abbott

    Editorial Boards:

    1. (1) European Stroke Journal: Editorial Board member (2) Terve Media: Visiting Editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. (1) Trial site-PI: Bayer (2) Trial site-PI: Amgen

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Nonrestricted grant from St. Jude Medical (2) Nonrestricted grant from Pfizer

    Research Support, Government Entities:

    1. (1) Helsinki-Uusimaa Hospital District, PI (2) Academy of Finland, PI

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. (1) Stock ownership: Vital Signum Ltd.

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Miikka Korja, MD, PhD
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaking fees/honoraria for lectures: (1) 2021: Association of Finnish Local and Regional Authorities, non-profit (1) 2019: KEVA, commercial (Finland’s largest pension provider) (2) 2019: Alma Media, commercial (3) 2018: Astellas, commercial (4) 2018: Professio, commercial Congress fees and travel expenses: (1) 2019: Microsoft, commercial (2) 2018: Medac, commercial (3) 2018: B. Braun Aesculap, commercial (4) 2017: Gartner Inc., commercial (5) 2017: Health 2.0 Ltd, commercial

    Editorial Boards:

    1. (1) Neurology, Editorial Board Member, 2021-

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. Own studies with potential for financial gain for the study investigators: (1) CleverHealth Network Project: AI Head Imaging study, 2018-ongoing; developing machine learning -based computer vision for head CT together with companies (Microsoft, CGI, Planmeca)

    Research Support, Commercial Entities:

    1. Financial or material support: (1) 2018-2021: CGI (2) 2018-2021: Planmeca (3) 2020-2021: Microsoft Stock/Stock Options, Medical Equipment & Materials: Stocks: (1) 2020: Faron Pharmaceuticals

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Departments of Neurosurgery (J.J.V., M.K.) and Neurology (D.S., J.P.), Helsinki University Hospital and University of Helsinki, Finland.
  1. Correspondence
    Dr. Virta jyri.virta{at}hus.fi
View Full Text

Article usage

Article usage: October 2021 to February 2023

AbstractFullPdfSource
Oct 20213399368Highwire
Nov 2021162814684Highwire
Dec 20214772222Highwire
Jan 2022184158Highwire
Feb 20222861717Highwire
Mar 202230278Highwire
Apr 202224289Highwire
May 202217453Highwire
Jun 202216086Highwire
Jul 202212811Highwire
Aug 202216720Highwire
Sep 202214522Highwire
Oct 202212252Highwire
Nov 2022164814Highwire
Dec 202211921Highwire
Jan 202310953Highwire
Feb 20238941Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me